Scientists are raising a provocative hypothesis about GLP-1 drugs for obesity: Perhaps targeting the GLP-1 hormone isn't ...

The California biotech has one therapy in Phase 1 testing and expects another to advance to the clinic later this year.

Nobel laureate Sir Michael Houghton and colleagues at Applied Pharmaceutical Innovation (API) outline how rigorous early ...

Cancer therapeutics and orphan drugs are no longer niche areas. Specialty drugs are now a significant portion of the prescription drug market, as well as the drug development pipeline, according to a ...

Nearly seven years after the FDA approved Novo Nordisk’s Ozempic for diabetes treatment, this medication and other GLP-1 receptor agonists have proven very effective in promoting weight loss. For the ...

The most familiar artificial intelligence (AI) applications include text generation, facial recognition, and autonomous driving. But there are other AI applications that deserve their share of ...

Novo employees already had access to a bespoke version of OpenAI’s ChatGPT but the new partnership goes beyond that, a ...

Merck MRK decided to discontinue two clinical development programs, namely KeyVibe and KEYFORM, which are evaluating its investigational cancer drugs vibostolimab and favezelimab, respectively.

Global Pediatric Development of Drugs, Biologics, and Medical Devices takes an in-depth look at creating and implementing a global regulatory strategy for bringing pediatric drug products and ...

The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.

The Danish drugmaker didn't disclose financial terms of the partnership announced Tuesday, which adds to Novo's existing AI ...